Lantern Pharma Announces FDA Clearance of IND for STAR-001 Pediatric CNS Cancer Trial
Lantern Pharma and its subsidiary Starlight Therapeutics announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application for STAR-001, enabling a planned Phase 1 pediatric clinical trial targeting central nervous system (CNS) cancers. The study will focus on rare and aggressive childhood brain tumors, including atypical teratoid rhabdoid tumors (ATRT), and may evaluate the therapy both alone and in combination with other agents to improve efficacy. This milestone advances Lantern Pharma’s AI-driven oncology pipeline and represents a key step toward developing new treatment options for pediatric patients with limited therapeutic alternatives. 
Lantern Pharma Announces FDA Clearance of IND for STAR-001 Pediatric CNS Cancer Trial